Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?
Authors:
Open Access
- 17 June 2022
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200135
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Clinical Benefit of Comprehensive Genomic Profiling for Advanced Cancers in IndiaJCO Global Oncology, 2022
- Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancerCancer Science, 2020
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLCNew England Journal of Medicine, 2020
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialCancer Discovery, 2017
- Mutational landscape and significance across 12 major cancer typesNature, 2013
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Past, Present and Future of Targeted Therapy in Solid TumorsCurrent Cancer Drug Targets, 2010
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005